CQCI Available Investigational PET Imaging Agents
| Radiopharmaceutical | IND# |
| 3’-deoxy-3’-[F 18]fluorothymidine:[F-18]FLT | 76843 |
| [11C]-PIB (N-Methyl-[11C] 2-(41-methylaminophenyl)-6-hydroxybenzothiazole | 104035 |
| 18F-39-F-6-OH-BTA1 also known as 18FGE067 (Flutemetamol) or 18F-PIB | 109760 |
| 1H-1-(3-[18F]-fluoro-2-hydroxy-propyl)-2-nitro-imidazole [18F]-fluoromisonidazole [18F]FMISO, FMISO | 111064 |
| 11C-Acetate or [C-11] Sodium Acetate | 113183 |
| H215O ([O-15] Water) | 113529 |
| 2-deoxy-2-[18F]fluoro-D-glucose (FDG) (non-cancer investigations) | 113858 |
| [18F]-Fluciclovine | 136875 |
| Radiopharmaceutical | ANDA# |
| 2-deoxy-2-[18F]fluoro-D-glucose (FDG) (cancer investigations) | 204498 |
| [18F] Sodium Fluoride (NaF) | 204497 |
Contact Us
Center for Quantitative Cancer Imaging Director
Jeffrey Yap, PhD
jeffrey.yap@hci.utah.edu
801-213-5650
Senior Advisor to the Director
John M. Hoffman, MD
john.hoffman@hci.utah.edu
801-587-4064
Governance
HCI Senior Director Oversight
David Gaffney, MD, PhD